Chemcon Speciality Chemicals makes the building-block molecules that go into medicines, oil wells and farm chemicals - a niche manufacturer that turns hazardous raw materials into high-purity intermediates its customers cannot easily switch away from. Founded in 1988 as Gujarat Quinone Private Limited by a first-generation entrepreneur whose group already spanned glass equipment and engineering plastics, the company grew from small-volume trading into a single-site industrial complex in Vadodara, Gujarat, adding one difficult chemistry after another over two decades. The recurring approach is to pick a molecule with a concentrated global supplier base, master the hazardous chemistry that keeps competitors out, then scale until it becomes one of the largest manufacturers of that product worldwide - a playbook it has run first with HMDS, then with CMIC, and now with bromides and newer organic intermediates.
Business segments
Two chemical verticals fed by a single manufacturing complex - one anchored by global leadership in two pharmaceutical intermediates, the other by a dominant domestic position in oilfield bromides, with a recently acquired third product line now entering the fold.
1. Organic chemicals: the pharmaceutical-intermediate engine
The company is the world's largest maker of CMIC and India's only maker of HMDS - two high-purity intermediates where customer approvals and hazardous raw-material handling create a barrier to entry that protects its position.
- Only Indian maker of HMDS - it is the sole domestic manufacturer of Hexamethyldisilazane, a silylating agent used in penicillin-group drugs and semiconductor processing, and the third-largest producer globally. More than 84% of HMDS revenue comes from the Indian market, where roughly 40% of demand is still met by imports, giving the company room to substitute those imports with its own output.
- Largest CMIC maker worldwide - its Chloromethyl Isopropyl Carbonate is the key intermediate for the anti-AIDS and anti-hepatitis B drug Tenofovir, and the company holds an estimated global share of more than 40%. It supplies two of the four major CMIC users in China and is working to qualify with the other two, so its customer base can expand without adding new chemistry.
- Backward-integrated into its own raw material - it makes TMCS, the basic input for HMDS, at a captive capacity of 2,400 metric tonnes per year, reducing dependence on Chinese imports that previously supplied roughly 70% of its raw-material needs. For CMIC, it now sources most of its key raw material MCF domestically from Paushak, with only 10-15% imported to maintain a parallel supplier.
- Newer molecules broaden the funnel - Bromobenzene, launched in 2023 at a 2,400-tonne-per-year plant, targets the agrochemical market and has drawn inquiries from global players, while 2-Bromo commenced in 2025 as a solvent and perfume intermediate. Together, the organic-chemicals plants have an installed capacity of 11,400 metric tonnes per year across HMDS, CMIC, Bromobenzene, 2-Bromo and ancillary products.
2. Inorganic bromides: the oilfield-completion franchise
The company is India's only manufacturer of Zinc Bromide and its largest maker of Calcium Bromide - clear-brine fluids that oil drillers pump into wells to control pressure, where domestic dominance matters more than global share.
- Completion fluids, not commodities - its Calcium Bromide, Zinc Bromide and Sodium Bromide are salty solutions used to clean wellbores after drilling and to hold down-hole pressure before production starts, making them essential consumables in upstream oil and gas operations. The segment contributed 13% of total business in FY2021, a smaller but steady counterweight to the pharma-intermediate engine.
- India's sole Zinc Bromide supplier - it is the only domestic producer of Zinc Bromide and the largest domestic producer of Calcium Bromide, giving it a position that import-dependent Indian oilfield-service companies cannot easily replicate. Its global share across all bromide capacity is around 3%, so the moat is local rather than worldwide.
- Capacity to serve demand swings - the inorganic-chemicals plants have an installed capacity of 15,000 metric tonnes per year, giving the company headroom when drilling activity picks up, though the business is sensitive to crude-oil price cycles and geopolitical uncertainty.
Manufacturing backbone
Nine plants on a single site handle everything from raw-material receipt to finished-product dispatch - a concentrated complex where hazardous-chemical expertise is the real asset.
- One location, nine dedicated plants - all manufacturing sits at Manjusar near Vadodara, Gujarat, where the site has grown from seven plants in FY2021 to nine operational plants and six owned warehouses by FY2024, with two more plants under process for commissioning in early FY2027. Each plant is dedicated to a specific product line - HMDS, high-purity HMDS, CMIC, multipurpose pharma intermediates, and oilwell chemicals - so cross-contamination risk is designed out.
- Hazardous chemistry as a moat - the company routinely handles bromine, methyl chloroformate and trimethyl chlorosilane, some of which are phosgenated and siliconized, requiring technical skill that takes years to build and that regulators do not easily license. It is a zero-discharge site, complying with India's water and air pollution-control acts, and has invested about ₹10 crore in a 2.1 MW captive solar plant to reduce energy-cost volatility.
- Raw-material-plus pricing - it prices its specialty chemicals on a cost-plus-raw-material basis, passing input-cost swings through to customers and protecting margins from the commodity cycles that affect its feedstock. Long-standing supplier relationships and a dedicated supply-chain team keep raw materials flowing at competitive prices, while currency risk is managed by monitoring rupee movements and taking hedging actions.
Group structure and partners
A standalone company with no subsidiaries or joint ventures, recently expanded by acquiring a promoter-group chemical business in a slump sale.
- No group entities - Chemcon reports on a standalone basis and has no subsidiaries, associate companies or joint ventures, so the listed entity is the entire operating business.
- Promoter-group acquisition in FY2026 - it acquired the entire business undertaking of Shivam Petrochem Industries, a partnership firm within the promoter group, for ₹36 crore through a slump sale completed in December 2025. Shivam Petrochem brings a new range of products including Trityl Chloride, TosMIC and pyridine derivatives, widening the company's presence into bulk drugs, chemical intermediates and solvents.
- Related-party land purchases - the company bought land parcels at Gothda near Vadodara in October 2022 from promoter and promoter-group sellers, securing ground for future expansion close to its existing Manjusar complex.